购物车
- 全部删除
- 您的购物车当前为空
SEP-363856 是一种口服活性和 CNS 活性的精神药物,具有独特的非 D2/5-HT2A 作用机制,发挥其抗精神病样作用,具有治疗精神分裂症的潜力。
SEP-363856 是一种口服活性和 CNS 活性的精神药物,具有独特的非 D2/5-HT2A 作用机制,发挥其抗精神病样作用,具有治疗精神分裂症的潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 1-2周 | |
50 mg | ¥ 13,800 | 1-2周 | |
100 mg | ¥ 17,500 | 1-2周 |
产品描述 | SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. |
靶点活性 | 5-HT1A receptor:2.3 μM (EC50), 5-HT1D receptor:0.262 μM (EC50), 5-HT2C receptor:30 μM (EC50), 5-HT2A receptor:10 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), 5-HT7 receptor:6.7 μM (EC50), TAAR1:0.140 μM (EC50) |
体外活性 | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
体内活性 | SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time. |
别名 | SEP-856 |
分子量 | 183.27 |
分子式 | C9H13NOS |
CAS No. | 1310426-33-5 |
密度 | 1.123 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容